LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Akcijų sąrašas・Incyte Corp

Incyte Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

95.13 -0.14

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

94.04

Max

96.24

Pagrindiniai rodikliai
By Trading Economics
Pajamos	4.1M 303M
Pardavimai	-234M 1.3B
P/E Sektoriaus vid.	14.17 51.415
Pelnas, tenkantis vienai akcijai	1.81
Pelno marža	23.834
Darbuotojai	2,844
EBITDA	-47M 367M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+14.5% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-28

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	993M 20B
Ankstesnė atidarymo kaina	95.27
Ankstesnė uždarymo kaina	95.13

Naujienos nuotaikos

By Acuity

46%

54%

145 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

59.52 / 62.66 Palaikymas ir pasipriešinimas

Incyte Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-18 23:10; UTC

Karštos akcijos

Stocks to Watch: Agilysys, XP

2026-05-18 18:44; UTC

Pagrindinės rinkos jėgos

Claritev Shares Recover After Comments About DOJ

2026-05-18 23:55; UTC

Uždarbis

Review & Preview: Earnings' Last Gasp -- Barrons.com

2026-05-18 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-18 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-18 23:37; UTC

Rinkos pokalbiai

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

2026-05-18 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

2026-05-18 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

2026-05-18 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

2026-05-18 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

2026-05-18 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

2026-05-18 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-18 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-18 20:25; UTC

Uždarbis

Correct: XP 1Q Total Client Assets BRL1.53T

2026-05-18 20:23; UTC

Uždarbis

XP 1Q Total Client Assets BRL1.53B

2026-05-18 20:19; UTC

Uždarbis

XP 1Q Adj EPS BRL2.49 >XP

2026-05-18 20:19; UTC

Uždarbis

XP 1Q Rev BRL4.73B >XP

2026-05-18 19:10; UTC

Rinkos pokalbiai

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

2026-05-18 19:00; UTC

Uždarbis

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

2026-05-18 18:52; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

2026-05-18 18:17; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

2026-05-18 17:22; UTC

Rinkos pokalbiai

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

2026-05-18 16:57; UTC

Įsigijimai, susijungimai, perėmimai

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

2026-05-18 16:57; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-05-18 16:57; UTC

Rinkos pokalbiai

Commodities Higher as Traders Want Physical Assets -- Market Talk

2026-05-18 16:54; UTC

Įsigijimai, susijungimai, perėmimai

Vinci Doesn't Set Out Financial Details of Deal

2026-05-18 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

2026-05-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

2026-05-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

2026-05-18 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Vinci Buys Canada's Modern Group of Companies

Akcijų palyginimas

Kainos pokytis

Incyte Corp Prognozė

Kainos tikslas

By TipRanks

14.5% į viršų

12 mėnesių prognozė

Vidutinis 109.13 USD 14.5%

Aukščiausias 135 USD

Žemiausias 75 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Incyte Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

17 ratings

Pirkti

Laikyti

Parduoti

Remiantis 17 analitikų, pateikusių Incyte Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

59.52 / 62.66Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

145 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation